Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine Gets $1.1M SBIR Grant to Develop 50 Cancer Biomarker Assays

NEW YORK (GenomeWeb News) — The National Cancer Institute has given Rules-Based Medicine a $1.1 million Phase I/Phase II Small Business Innovation Research contract to develop immunoassays for cancer, the biomarker testing company said today.
 
Austin, Texas-based RBM said it will use the cash to develop 50 new quantitative, multiplexed immunoassays for cancer-related proteins to add to its Human Multi-Analyte Profile platform.
 
RBM said its testing service, which is CLIA certified and supports Good Lab Practice studies, can generate data for hundreds of proteins "from a small sample volume and from multiple species."

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.